(in million €) H2 2016 H2 2017 2016 2017
Recurring EBITDA (12) (10) (26) (24)
Recurring EBIT (18) (16) (39) (36)
of which associates 5 10 7 18
Total EBIT (26) (19) (50) (51)
R&D expenditure 4 0 8 5
Capital expenditure 6 7 10 12
Capital employed, end of period 137 174 137 174
Capital employed, average 155 161 158 152
Workforce, end of period (fully consolidated) 984 1,009 984 1,009
Workforce, end of period (associates) 1,752 2,443 1,752 2,443